首页> 美国卫生研究院文献>The Korean Journal of Internal Medicine >Achalasia: treatment current status and future advances
【2h】

Achalasia: treatment current status and future advances

机译:失语症:治疗现状和未来进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Achalasia was first described in the 17th century and its treatment continues to be challenging. Palliative treatment involves disruption of the lower esophageal sphincter, which can be accomplished mechanically (balloon dilation or surgical myotomy) or chemically (Botox). True surgical treatment originated some 100 years ago and remained largely unchanged until the advent of thoracoscopic and then laparoscopic myotomy beginning in the 1980s. Because these procedures provided relatively definitive treatment and were well tolerated by patients, minimal invasive surgery assumed a primary role in the treatment algorithms for achalasia. In 2008, an endoscopic (incision-less) myotomy approach, per-oral endoscopic myotomy, was described. This even less invasive approach has rapidly been adopted in the majority of high-volume achalasia centers. Newer interventions, such as stenting and cell transplant, are under active investigation.
机译:失语症最早在17世纪被描述,其治疗仍然具有挑战性。姑息治疗涉及食管下括约肌的破坏,可以机械地(气球扩张或外科肌切开术)或化学地(肉毒杆菌毒素)来完成。真正的外科治疗起源于大约100年前,直到1980年代开始进行胸腔镜和腹腔镜肌切开术之前,基本上没有任何改变。由于这些程序提供了相对明确的治疗方法,并且患者可以很好地耐受,因此微创手术在门失弛缓症的治疗方法中起着主要作用。 2008年,描述了一种内镜(无切口)肌切开术,即经口内镜下肌切开术。这种侵入性较小的方法已在大多数高容量门失弛缓症中心迅速采用。较新的干预措施,如支架植入术和细胞移植,正在积极研究中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号